Mirati Turns to Markets for $56.9M Raise
A new underwritten public offering of about 3.25 million shares of common stock by Mirati Therapeutics Inc. will support the company’s Phase I/II push for cancer candidates MGCD265 and MGCD516, as well as an open-label, dose-confirmation trial of its late-stage candidate mocetinostat. Mirati will price the stock at $17.50 per share, and expects gross proceeds of about $56.9 million.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST